Estimation of Global Pharmaceutical Production
The global pharmaceutical industry produces a substantial volume of medicines annually. Based on available data, the market value was approximately USD 1,661 billion in 2023, with projections indicating growth to USD 2,350 billion by 2030. 25 However, in terms of physical production volume, estimates for pharmaceuticals and personal care products (PPCPs) combined suggest over 20 million tons are manufactured each year, a significant portion of which pertains to medicines. 14 This figure encompasses active pharmaceutical ingredients (APIs) and formulations, though precise disaggregation for medicines alone is challenging without more granular data.
Estimation of Unabsorbed Drugs Passing Through the Body
A considerable proportion of administered pharmaceuticals is not fully absorbed or metabolized and is excreted unchanged, primarily through urine and feces. Studies indicate that this varies by drug class: for instance, drugs with high metabolism exhibit low unchanged excretion (often below 10%), while others with lower metabolism can see 50% or more excreted intact. 0 On average, across common pharmaceuticals, approximately 10-30% may pass through the body unchanged, contributing to environmental release via wastewater. 3 This estimation accounts for pharmacokinetic variability, where renal clearance plays a key role in elimination.
Estimation of Pollution Quantities from the Pharmaceutical Industry
The pharmaceutical sector contributes to environmental pollution through manufacturing emissions, wastewater discharge, and post-consumer excretion. Global studies have detected over 600 APIs in waterways, with concentrations posing risks in some regions. 10 Manufacturing alone can release emissions ranging from 2 to 202 mg/m³ of volatile organic compounds and other pollutants, while untreated wastewater—estimated at 80% globally—exacerbates API dispersal. 17 Annually, thousands of tons of pharmaceuticals enter the environment, with a notable portion from the 20 million tons of PPCPs produced. 14 This includes greenhouse gas emissions equivalent to 20-25% of the industry’s environmental footprint. 11
Estimation of Extended Life Expectancy With and Without Modern Medications
Global life expectancy has risen significantly since the early 20th century, from around 47 years in 1900 to approximately 78 years in developed nations by 2013, though gains have slowed recently. 67 Modern medications, including antibiotics and vaccines, have contributed modestly, accounting for an estimated 5-10 years of extension, as evidenced by reductions in mortality from conditions like pneumonia and maternal deaths (e.g., 25-40% decline due to sulfa drugs). 71 Without these interventions, life expectancy might be 10-15 years lower globally, but historical declines in mortality prior to widespread medication use—primarily from infectious diseases—were driven more by sanitation, hygiene, and public health measures, which reduced rates by over two-thirds from 1900 onward. 66 72 Behavioral and social factors have exerted larger influences than healthcare alone. 33
Effects of Drug Production and Pollution on Life Expectancy
Pharmaceutical production and associated pollution, including API releases, contribute to broader environmental degradation that reduces global life expectancy by approximately 1.8-2.2 years on average, with air pollution (partly from industrial emissions) being a primary factor. 59 62 Specific to pharma pollution, effects are localized but include endocrine disruptions in aquatic systems, indirectly impacting human health through ecosystem services. Overall, pollution from fossil fuels and industry shaves 1.1-1.7 years off life expectancy without mitigation. 56 While pharma’s direct contribution is smaller than sectors like transportation, its greenhouse gas emissions exceed those of the automotive industry by 13%. 16